Corticosteroids as adjunctive therapy in the treatment of coronavirus disease 2019 : A report of two cases and literature review
Copyright © 2020. Published by Elsevier Ltd..
The effect of systemic corticosteroids on clinical outcomes in patients with coronavirus disease 2019 (COVID-19) remains controversial. While the use of corticosteroids raises concerns regarding delayed viral clearance, secondary infections, and long-term complications that can lead to increased mortality, corticosteroids have the potential to reduce mortality if used appropriately. Herein, we report good outcomes in two patients with COVID-19 who received systemic corticosteroids as adjunctive therapy. An 83-year-old man with hypertension and smoking history and a 62-year-old man with a drinking habit were transferred to our hospital with a diagnosis of COVID-19. The patients developed general malaise and loss of appetite with persistent high fever. Despite the prescription of antiviral drugs, their hypoxemia progressed rapidly. However, after the introduction of systemic corticosteroids, their symptoms improved as the fever decreased, and their hypoxemia gradually improved. These results suggest that some patients with COVID-19 may benefit from the appropriate use of systemic corticosteroids as adjunctive therapy.
| Media Type: |
Electronic Article |
|---|
| Year of Publication: |
2021 |
|---|
| Contained In: |
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy - Vol. 27, No. 1 (2021), p. 94-98 |
|---|
| Language: |
English |
|---|
| Contributors: |
Kosaka, Makoto |
|---|
| Links: |
|---|
| Notes: |
Date Completed 23.11.2020 Date Revised 10.01.2021 published: Print-Electronic Citation Status MEDLINE Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine |
|---|
| Physical Description: |
Online-Ressource |
|---|
| doi: |
10.1016/j.jiac.2020.09.007 |
|---|---|
| PMID: |
32988730 |
| PPN (Catalogue-ID): |
NLM316557358 |
|---|
| LEADER | 04754nma a2200961 c 4500 | ||
|---|---|---|---|
| 001 | NLM316557358 | ||
| 003 | DE-601 | ||
| 005 | 20210111234316.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200930s2021 000 0 eng d | ||
| 024 | 7 | |a 10.1016/j.jiac.2020.09.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed21n1103.xml |
| 035 | |a S1341-321X(20)30327-5 | ||
| 035 | |a (DE-599)NLM32988730 | ||
| 040 | |b ger |c GBVCP | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Kosaka, Makoto | |
| 245 | 1 | 0 | |a Corticosteroids as adjunctive therapy in the treatment of coronavirus disease 2019 |h Elektronische Ressource |b A report of two cases and literature review |
| 300 | |a Online-Ressource | ||
| 500 | |a Date Completed 23.11.2020 | ||
| 500 | |a Date Revised 10.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 500 | |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine | ||
| 520 | |a Copyright © 2020. Published by Elsevier Ltd. | ||
| 520 | |a The effect of systemic corticosteroids on clinical outcomes in patients with coronavirus disease 2019 (COVID-19) remains controversial. While the use of corticosteroids raises concerns regarding delayed viral clearance, secondary infections, and long-term complications that can lead to increased mortality, corticosteroids have the potential to reduce mortality if used appropriately. Herein, we report good outcomes in two patients with COVID-19 who received systemic corticosteroids as adjunctive therapy. An 83-year-old man with hypertension and smoking history and a 62-year-old man with a drinking habit were transferred to our hospital with a diagnosis of COVID-19. The patients developed general malaise and loss of appetite with persistent high fever. Despite the prescription of antiviral drugs, their hypoxemia progressed rapidly. However, after the introduction of systemic corticosteroids, their symptoms improved as the fever decreased, and their hypoxemia gradually improved. These results suggest that some patients with COVID-19 may benefit from the appropriate use of systemic corticosteroids as adjunctive therapy | ||
| 611 | 2 | 7 | |a Case Reports |2 gnd |
| 611 | 2 | 7 | |a Journal Article |2 gnd |
| 611 | 2 | 7 | |a Review |2 gnd |
| 653 | 2 | |a Adrenal Cortex Hormones |6 D000305 |a *therapeutic use |6 Q000627 | |
| 653 | 2 | |a Aged, 80 and over |6 D000369 | |
| 653 | 2 | |a Alcohol Drinking |6 D000428 |a epidemiology |6 Q000453 | |
| 653 | 2 | |a Antiviral Agents |6 D000998 |a therapeutic use |6 Q000627 | |
| 653 | 2 | |a Betacoronavirus |6 D000073640 | |
| 653 | 2 | |a COVID-19 |6 D000086382 | |
| 653 | 2 | |a Combined Modality Therapy |6 D003131 | |
| 653 | 2 | |a Coronavirus Infections |6 D018352 |a *drug therapy |6 Q000188 |a epidemiology |6 Q000453 | |
| 653 | 2 | |a Humans |6 D006801 | |
| 653 | 2 | |a Hypertension |6 D006973 |a epidemiology |6 Q000453 | |
| 653 | 2 | |a Lung |6 D008168 |a diagnostic imaging |6 Q000000981 | |
| 653 | 2 | |a Male |6 D008297 | |
| 653 | 2 | |a Methylprednisolone |6 D008775 |a *therapeutic use |6 Q000627 | |
| 653 | 2 | |a Middle Aged |6 D008875 | |
| 653 | 2 | |a Pandemics |6 D058873 | |
| 653 | 2 | |a Pneumonia, Viral |6 D011024 |a *drug therapy |6 Q000188 |a epidemiology |6 Q000453 | |
| 653 | 2 | |a SARS-CoV-2 |6 D000086402 | |
| 653 | 2 | |a Smoking |6 D012907 |a epidemiology |6 Q000453 | |
| 653 | 2 | |a Stomach Neoplasms |6 D013274 |a epidemiology |6 Q000453 | |
| 653 | 2 | |a Tomography, X-Ray Computed |6 D014057 | |
| 653 | 2 | |a Treatment Outcome |6 D016896 | |
| 655 | 7 | |a Acute respiratory distress syndrome |2 gnd | |
| 655 | 7 | |a Coronavirus disease 2019 |2 gnd | |
| 655 | 7 | |a Corticosteroids |2 gnd | |
| 655 | 7 | |a Methylprednisolone |2 gnd | |
| 655 | 7 | |a Severe acute respiratory syndrome coronavirus 2 |2 gnd | |
| 655 | 7 | |a Adrenal Cortex Hormones |2 gnd | |
| 655 | 7 | |a Antiviral Agents |2 gnd | |
| 655 | 7 | |a Methylprednisolone |2 gnd | |
| 655 | 7 | |a X4W7ZR7023 |2 gnd | |
| 689 | 0 | 0 | |A f |a Case Reports |
| 689 | 0 | 1 | |A f |a Journal Article |
| 689 | 0 | 2 | |A f |a Review |
| 689 | 0 | |5 DE-601 | |
| 689 | 1 | 0 | |a Acute respiratory distress syndrome |
| 689 | 1 | 1 | |a Coronavirus disease 2019 |
| 689 | 1 | 2 | |a Corticosteroids |
| 689 | 1 | 3 | |a Methylprednisolone |
| 689 | 1 | 4 | |a Severe acute respiratory syndrome coronavirus 2 |
| 689 | 1 | |5 DE-601 | |
| 689 | 2 | 0 | |a Adrenal Cortex Hormones |
| 689 | 2 | 1 | |a Antiviral Agents |
| 689 | 2 | 2 | |a Methylprednisolone |
| 689 | 2 | 3 | |A r |a X4W7ZR7023 |
| 689 | 2 | |5 DE-601 | |
| 700 | 1 | |a Yamazaki, Yoshitaka | |
| 700 | 1 | |a Maruno, Takashi | |
| 700 | 1 | |a Sakaguchi, Koji | |
| 700 | 1 | |a Sawaki, Shoji | |
| 773 | 0 | 8 | |i in |t Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |g Vol. 27, No. 1 (2021), p. 94-98 |q 27:1<94-98 |w (DE-601)NLM095490736 |x 1437-7780 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.jiac.2020.09.007 |3 Volltext |
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 1 |b 30 |c 01 |h 94-98 | ||